{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:39:22Z","timestamp":1793284762894,"version":"4.5.0"},"reference-count":58,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,7,21]]},"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the comparative efficacy of traditional non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclo-oxygenase-2 inhibitors in patients with acute gout.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>Medline, Web of Science, China National Knowledge Infrastructure and Wanfang Data published as of 4 April 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed meta-analysis of randomised controlled trials (RCTs) of traditional non-selective NSAIDs versus cyclo-oxygenase-2 inhibitors and RCTs of various cyclo-oxygenase-2 inhibitors in patients with acute gout. The main outcome measures were mean change in pain Visual Analogue Scale (VAS) score and 5-point Likert scale score on days 2\u20138.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-four trials involving five drugs were evaluated. For pain Likert scale, etoricoxib was comparable to indomethacin (standardised mean difference (SMD): \u22120.09, 95%\u2009CI: \u22120.27 to 0.08) but better than diclofenac 50\u2009mg three times a day (SMD: \u22120.53, 95%\u2009CI: \u22120.98 to 0.09). Regarding pain VAS score, etoricoxib was comparable to diclofenac 75\u2009mg two times per day (SMD: \u22121.63, 95%\u2009CI: \u22124.60 to 1.34) and diclofenac 75\u2009mg one time a day (SMD: \u22121.82, 95%\u2009CI: \u22125.18 to 1.53), while celecoxib was comparable to diclofenac 100\u2009mg one time a day (SMD: \u22122.41, 95%\u2009CI: \u22125.91 to 1.09). Etoricoxib showed similar patients\u2019 global assessment of response (SMD: \u22120.10, 95%\u2009CI: \u22120.27 to 0.07) and swollen joint count (SMD: \u22120.25, 95%\u2009CI: \u22120.74 to 0.24), but better investigator\u2019s global assessment of response (SMD: \u22120.29, 95%\u2009CI: \u22120.46 to 0.11) compared with indomethacin. Etoricoxib showed more favourable pain VAS score than celecoxib (SMD: \u22122.36, 95%\u2009CI: \u22123.36 to 1.37), but was comparable to meloxicam (SMD: \u22124.02, 95%\u2009CI: \u221210.28 to 2.24). Etoricoxib showed more favourable pain Likert scale than meloxicam (SMD: \u22120.56, 95%\u2009CI: \u22121.10 to 0.02). Etoricoxib 120\u2009mg one time a day was more likely to achieve clinical improvement than celecoxib 200\u2009mg two times per day (OR: 4.84, 95%\u2009CI: 2.19 to 10.72).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although cyclo-oxygenase-2 inhibitors and traditional non-selective NSAIDs may be equally beneficial in terms of pain relief, cyclo-oxygenase-2 inhibitors (especially etoricoxib) may confer a greater benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2019-036748","type":"journal-article","created":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T02:30:59Z","timestamp":1599791459000},"page":"e036748","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":23,"title":["Comparative efficacy of traditional non-selective NSAIDs and selective cyclo-oxygenase-2 inhibitors in patients with acute gout: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"10","author":[{"given":"Mengtao","family":"Li","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3883-2318","authenticated-orcid":false,"given":"Xiaofeng","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"key":"2026062608014483000_10.9.e036748.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00346-9"},{"key":"2026062608014483000_10.9.e036748.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204647"},{"key":"2026062608014483000_10.9.e036748.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.91"},{"key":"2026062608014483000_10.9.e036748.4","first-page":"1823","article-title":"Chinese Society of rheumatology guideline for the management of gout","volume":"2017","author":"Zeng","year":"2016","journal-title":"Zhejiang Medical Journal"},{"key":"2026062608014483000_10.9.e036748.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209707"},{"key":"2026062608014483000_10.9.e036748.6","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21772"},{"key":"2026062608014483000_10.9.e036748.7","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21773"},{"key":"2026062608014483000_10.9.e036748.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.055269"},{"key":"2026062608014483000_10.9.e036748.9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem056a"},{"key":"2026062608014483000_10.9.e036748.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60883-7"},{"key":"2026062608014483000_10.9.e036748.11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.21.2857"},{"key":"2026062608014483000_10.9.e036748.12","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1182\/blood.V91.5.1769","article-title":"Monosodium urate microcrystals induce cyclooxygenase-2 in human monocytes","volume":"91","author":"Pouliot","year":"1998","journal-title":"Blood"},{"key":"2026062608014483000_10.9.e036748.13","article-title":"Non-steroidal anti-inflammatory drugs for acute gout","author":"van Durme","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026062608014483000_10.9.e036748.14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10067-015-2991-1","article-title":"Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis","volume":"35","author":"Zhang","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2026062608014483000_10.9.e036748.15","first-page":"30","article-title":"The clinical effect of different analgesic anti \u2013 inflammatory solution in the treatment of acute gouty arthritis","volume":"9","author":"Cui","year":"2016","journal-title":"Chin J of Clinical \uff32ational Drug Use"},{"key":"2026062608014483000_10.9.e036748.16","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199651030-00007"},{"key":"2026062608014483000_10.9.e036748.17","unstructured":"Liu CJ . Analysis of the efficacy and safety of etoricoxib and meloxicam in the treatment of acute gout. Medicine & people 2015:369\u201370."},{"key":"2026062608014483000_10.9.e036748.18","unstructured":"Guo DB , YJ J , RP L , et al . Clinical efficacy and safety of etoricoxib and meloxicam in treating acute gout. China Modern Medicine 2014:68\u20139."},{"key":"2026062608014483000_10.9.e036748.19","first-page":"114","article-title":"Comparative clinical efficacy of etoricoxib and meloxicam in the treatment of acute gout","volume":"12","author":"Li","year":"2017","journal-title":"China Practical Medicine"},{"key":"2026062608014483000_10.9.e036748.20","first-page":"221","article-title":"Evaluation of efficacy and safety of etoricoxib and meloxicam in the treatment of patients with acute gout","volume":"31","author":"Zhang","year":"2012","journal-title":"Chin J Geriatr"},{"key":"2026062608014483000_10.9.e036748.21","first-page":"44","article-title":"Comparative efficacy of etoricoxib and celecoxib for the treatment of patients with acute gout","volume":"22","author":"Hong","year":"2013","journal-title":"China Pharmaceuticals"},{"key":"2026062608014483000_10.9.e036748.22","first-page":"156","article-title":"The efficacy and safety of etoricoxib and celecoxib in the treatment of acute gout","volume":"34","author":"Xia","year":"2015","journal-title":"China & Foreign Medical Treatment"},{"key":"2026062608014483000_10.9.e036748.23","first-page":"264","article-title":"Comparative clinical efficacy and safety of etoricoxib and meloxicam in the treatment of acute gout","volume":"26","author":"Zhou","year":"2016","journal-title":"China Health Care & Nutrition"},{"key":"2026062608014483000_10.9.e036748.24","first-page":"49","article-title":"Comparative clinical efficacy of etoricoxib and celecoxib in the treatment of acute gout","volume":"13","author":"Ming","year":"2016","journal-title":"Journal of Northern Pharmacy"},{"key":"2026062608014483000_10.9.e036748.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780200320"},{"key":"2026062608014483000_10.9.e036748.26","first-page":"S38","article-title":"Cochrane Handbook for systematic reviews of interventions","volume":"5","author":"Higgins","year":"2011","journal-title":"Naunyn-Schmiedebergs Archiv f\u00fcr experimentelle Pathologie und Pharmakologie"},{"key":"2026062608014483000_10.9.e036748.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.01.032"},{"key":"2026062608014483000_10.9.e036748.28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12961-018-0320-2","article-title":"The grade evidence to decision (ETD) framework for health system and public health decisions","volume":"16","author":"Moberg","year":"2018","journal-title":"Health Res Policy Syst"},{"key":"2026062608014483000_10.9.e036748.29","first-page":"S38","article-title":"Cochrane Handbook for systematic reviews of interventions version 5.1.0","volume":"5","author":"Higgins Jpt","year":"2011","journal-title":"Naunyn-Schmiedebergs Archiv f\u00fcr experimentelle Pathologie und Pharmakologie"},{"key":"2026062608014483000_10.9.e036748.30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7352.1488"},{"key":"2026062608014483000_10.9.e036748.31","doi-asserted-by":"publisher","DOI":"10.1002\/art.20007"},{"key":"2026062608014483000_10.9.e036748.32","unstructured":"Ye Q , PF D , Wang ZZ , et al . Effect of etoricoxib on acute gout. Clinical Education of General Practice 2010:391\u20133."},{"key":"2026062608014483000_10.9.e036748.33","first-page":"33","article-title":"Evaluation of analgesic effect ofetoricoxib in the treatment of 140 patients with acute gout","volume":"22","author":"Gao","year":"2013","journal-title":"China Pharmaceuticals"},{"key":"2026062608014483000_10.9.e036748.34","article-title":"Etoricoxib versus indometacin in the treatment of Chinese patients with acute gouty arthritis: a randomized double-blind trial","volume":"126","author":"Li","year":"2013","journal-title":"Chin Med J"},{"key":"2026062608014483000_10.9.e036748.35","first-page":"5747","article-title":"Evaluation of efficacy of COX-2 inhibitors in the treatment of patients with acute gouty arthritis","volume":"14","author":"Guo","year":"2014","journal-title":"Progress in Modern Biomedicine"},{"key":"2026062608014483000_10.9.e036748.36","unstructured":"JL L . Clinical efficacy of etoricoxib in the treatment of acute gouty arthritis. Practical Pharmacy And Clinical Remedies 2014:451\u20134."},{"key":"2026062608014483000_10.9.e036748.37","first-page":"247","article-title":"Efficacy of etoricoxib in the treatment of acute gout","volume":"25","author":"Kuang","year":"2015","journal-title":"China Health Care & Nutrition"},{"key":"2026062608014483000_10.9.e036748.38","unstructured":"Zhu HY . Clincal efficacy of etoricoxib in the treatment of 50 patients with acute gout. Medical Information 2015:380\u20131."},{"key":"2026062608014483000_10.9.e036748.39","first-page":"2447","article-title":"Analysis of the clinical effect and safety of cyclooxygenase -2(COX-2)inhibitors of etoricoxib in treatment of acute gout arthritis","volume":"37","author":"SJ","year":"2016","journal-title":"Jilin Medical Journal"},{"key":"2026062608014483000_10.9.e036748.40","first-page":"107","article-title":"Efficacy study of etoricoxib in the treatment of acute severe gouty arthritis","volume":"14","author":"Pan","year":"2016","journal-title":"Guide of China Medicine"},{"key":"2026062608014483000_10.9.e036748.41","first-page":"47","article-title":"Comparative analysis of clinical effect and safety of celecoxib and etocoxib in the treatment of acute gout","volume":"2","author":"Gao","year":"2018","journal-title":"Modern Medicine and Health \uff32esearch"},{"key":"2026062608014483000_10.9.e036748.42","first-page":"102","article-title":"Comparison of the clinical efficacy and inflammatory changes of etocoxib and celecoxib in the treatment of acute gout","volume":"8","author":"Lan","year":"2018","journal-title":"Medical Frontier"},{"key":"2026062608014483000_10.9.e036748.43","first-page":"93","article-title":"Clinical study on the improvement of inflammatory factor and pain in patients with actue gout with treatment of etoricoxib","volume":"31","author":"Sheng","year":"2019","journal-title":"Strait Pharmaceutical Journal"},{"key":"2026062608014483000_10.9.e036748.44","unstructured":"LL W , Yang YH . Analysis of effect of etocoxib and meloxicam in the treatment acute gouty arthritis. Health Guide 2019;11."},{"key":"2026062608014483000_10.9.e036748.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2014.01.001"},{"key":"2026062608014483000_10.9.e036748.46","article-title":"Non-Steroidal anti-inflammatory drugs for low back pain","author":"Roelofs","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"2026062608014483000_10.9.e036748.47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61909-6"},{"key":"2026062608014483000_10.9.e036748.48","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69666-9"},{"key":"2026062608014483000_10.9.e036748.49","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.10.1247"},{"key":"2026062608014483000_10.9.e036748.50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/862153","article-title":"Cardiorenal effects of newer NSAIDs (celecoxib) versus classic NSAIDs (ibuprofen) in patients with arthritis","volume":"2011","author":"Hegazy","year":"2011","journal-title":"J Toxicol"},{"key":"2026062608014483000_10.9.e036748.51","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-200007030-00004"},{"key":"2026062608014483000_10.9.e036748.52","first-page":"480","article-title":"Do non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects?","volume":"15","author":"Giovanni","year":"2002","journal-title":"J Nephrol"},{"key":"2026062608014483000_10.9.e036748.53","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c7086"},{"key":"2026062608014483000_10.9.e036748.54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611593"},{"key":"2026062608014483000_10.9.e036748.55","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.amjmed.2017.06.028","article-title":"The risk of major NSAID toxicity with celecoxib, ibuprofen, or naproxen: a secondary analysis of the precision trial","volume":"130","author":"Solomon","year":"2017","journal-title":"Am J Med"},{"key":"2026062608014483000_10.9.e036748.56","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60799-0"},{"key":"2026062608014483000_10.9.e036748.57","doi-asserted-by":"publisher","DOI":"10.1185\/03007999109111513"},{"key":"2026062608014483000_10.9.e036748.58","doi-asserted-by":"publisher","DOI":"10.1136\/ard.36.1.80"}],"updated-by":[{"DOI":"10.1136\/bmjopen-2019-036748corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T00:00:00Z","timestamp":1602633600000}}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-036748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:16:39Z","timestamp":1782486999000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-036748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":58,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9,10]]},"published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1136\/bmjopen-2019-036748"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-036748","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]}}}